- Investing.com
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients’ lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. It has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., Merck &Co., Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Mercer Island, Washington.
Metrics to compare | KANT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKANTPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.2x | −2.9x | −0.5x | |
PEG Ratio | 0.02 | 0.00 | 0.00 | |
Price/Book | −0.3x | 1.9x | 2.6x | |
Price / LTM Sales | - | 14.1x | 2.9x | |
Upside (Analyst Target) | - | 229.9% | 50.4% | |
Fair Value Upside | Unlock | 8.9% | 9.1% | Unlock |